DDInter364 DDInter1947
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, deb
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned using combinations of vorinostat with other drugs.
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Vorinostat
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vorinostat
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vorinostat
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Lisdexamfetamine
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vorinostat
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Dermatitis exfoliative
Dermatitis exfoliative {u} (Side Effect) is caused by {v} (Compound) Thalidomide
Thalidomide {u} may lead to a major life threatening interaction when taken with {v} Vorinostat
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Azelaic Acid
Azelaic Acid {u} (Compound) resembles {v} (Compound) Vorinostat
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) downregulates {v} (Gene) GRN
GRN {u} (Gene) is upregulated by {v} (Compound) Vorinostat
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} (Compound) downregulates {v} (Gene) ATP6V0B
ATP6V0B {u} (Gene) is upregulated by {v} (Compound) Vorinostat
Chlorpropamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vorinostat
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} (Compound) causes {v} (Side Effect) Gastrointestinal symptom NOS
Gastrointestinal symptom NOS {u} (Side Effect) is caused by {v} (Compound) Vorinostat
Chlorpropamide (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Vorinostat (Compound)
Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Vorinostat
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Vorinostat
Chlorpropamide (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Lisdexamfetamine (Compound) and Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Vorinostat
Chlorpropamide (Compound) causes Dermatitis exfoliative (Side Effect) and Dermatitis exfoliative (Side Effect) is caused by Thalidomide (Compound) and Thalidomide may lead to a major life threatening interaction when taken with Vorinostat
Chlorpropamide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Azelaic Acid (Compound) and Azelaic Acid (Compound) resembles Vorinostat (Compound)
Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide (Compound) downregulates GRN (Gene) and GRN (Gene) is upregulated by Vorinostat (Compound)
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide (Compound) downregulates ATP6V0B (Gene) and ATP6V0B (Gene) is upregulated by Vorinostat (Compound)
Chlorpropamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Vorinostat
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride (Compound) causes Gastrointestinal symptom NOS (Side Effect) and Gastrointestinal symptom NOS (Side Effect) is caused by Vorinostat (Compound)